Prof Alison McConnell of HSS’s iWell Research Centre has been part of an international, multi-centre placebo-controlled trial of adjunctive inspiratory muscle training for patients with chronic obstructive pulmonary disease (COPD). The trial, published in this month’s edition of the journal Thorax (impact factor 8.272) tested whether the addition of specific training of the inspiratory muscles enhanced the benefits to patients of traditional pulmonary rehabilitation programmes. It’s well-established that when undertaken separately, both interventions are effective; improving exercise tolerance, breathlessness and quality of life. However, there has been great controversy about whether adding the two interventions together provides superior outcomes.
The trial involved five centres in Europe and Canada, and 219 patients with COPD, taking 6 years to complete. The data indicated that exercise endurance time and breathlessness improved to a greater extent in patients who received rehabilitation plus inspiratory muscle training. The study also found that, irrespective of group allocation, those participants who achieved the greatest improvement in their inspiratory muscle function, also showed the greatest improvements in functional and clinical outcomes.
The full paper is available via Open Access here:
http://thorax.bmj.com/content/thoraxjnl/early/2018/06/18/thoraxjnl-2017-211417.full.pdf











Beyond Academia: Exploring Career Options for Early Career Researchers – Online Workshop
UKCGE Recognised Research Supervision Programme: Deadline Approaching
SPROUT: From Sustainable Research to Sustainable Research Lives
BRIAN upgrade and new look
Seeing the fruits of your labour in Bangladesh
ECR Funding Open Call: Research Culture & Community Grant – Apply now
ECR Funding Open Call: Research Culture & Community Grant – Application Deadline Friday 12 December
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease